RxDoctor Payments Data

Philip Shalhoub, MD

Urology · Roseville, MINPI 1992960249

Payments from drug & device makers

$15,151in general payments, 2019–2025

Across 504 payments — averaging $30.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$2K
  • Procept Biorobotics Corporation$1K
  • Neotract Inc.$1K
  • Astellas Pharma US Inc$968
  • Olympus Corporation Of The Americas$812
  • AbbVie$767
  • plus $8K from 51 others

What the payments were for

  • Travel & lodging$2,46916%
  • Food & beverage$12,28581%
  • Education$3973%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,151 in reported general payments places this provider in the 80th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$226,588
Medicare patients
544
Services billed
2,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abiraterone Acetate26$163,279
MyrbetriqMirabegron109$87,342
GemtesaVibegron60$37,460
Mirabegron ErMirabegron45$23,972
Tamsulosin Hcl796$15,689
Methenamine Hippurate39$4,744
Alfuzosin Hcl ErAlfuzosin Hcl118$3,439
Estradiol36$3,048
Finasteride174$2,397
Tolterodine Tartrate ErTolterodine Tartrate26$1,642
Solifenacin Succinate50$1,301
Oxybutynin Chloride ErOxybutynin Chloride36$1,111
Bicalutamide16$545
Testosterone Cypionate18$402
Oxybutynin Chloride30$288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Janssen Scientific Affairs, LLCAbiraterone Acetate$263$163,27926 claims
Astellas Pharma US IncMyrbetriq$968$87,342109 claims
Sumitomo Pharma America, Inc.Gemtesa$238$37,46060 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 400 urology providers in Michigan.

Other urology in Roseville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →